<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medication options for prevention of postpartum hemorrhage after birth&lt;sup&gt;[1-5]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medication options for prevention of postpartum hemorrhage after birth<sup>[1-5]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Medication options for prevention of postpartum hemorrhage after birth<sup>[1-5]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Considerations</td> <td class="subtitle1">Major side effects</td> </tr> <tr> <td>Oxytocin</td> <td> <p><strong>IV infusion (preferred):</strong> Example regimen<sup>[1]</sup></p> Use 10 to 30 units in 500 mL normal saline or 20 to 60 units in 1000 mL normal saline: <ul class="decimal_heading"> <li>Initial: 10 units over 30 minutes</li> <li>Maintenance: 7.5 units over 60 minutes </li> </ul> <p class="extra_spacing_top"><strong>IM (alternative where IV access is unavailable):</strong> 10 units once.</p> </td> <td>Standard of care for most patients in the United States with or without other uterotonic medications.</td> <td> <p>Generally well tolerated.</p> <p>Flushing, gastrointestinal (eg, nausea, vomiting).</p> <p>Risk of hypotension, tachycardia, and myocardial ischemia with rapid IV administration of high doses.</p> Risk of hyponatremia (rare) with large doses given for a prolonged period due to water retention.</td> </tr> <tr> <td>Misoprostol</td> <td> <p><strong>Buccal/sublingual:</strong> 200 to 400 mcg once.</p> <strong>Oral (alternative route where oxytocin is unavailable):</strong> 600 mcg once.</td> <td>May also be administered rectally; however, onset may be delayed relative to buccal/sublingual.</td> <td>Shivering, fever, gastrointestinal (eg, diarrhea, vomiting), headache.</td> </tr> <tr> <td>Ergot alkaloids <ul class="decimal_heading"> <li>Methylergonovine (methylergometrine)</li> <li>Ergonovine (ergometrine; not available in the United States)</li> </ul> </td> <td><strong>IM:</strong> 0.2 mg once.</td> <td>Due to vasoconstrictive effects, contraindicated in patients with hypertension (including preeclampsia/eclampsia), history of migraine, or vascular disease (eg, Raynaud phenomenon).</td> <td> <p>Often not well tolerated due to vasoconstrictive adverse effects.</p> Cardiovascular (eg, elevated blood pressure, myocardial ischemia), headache, increase in postpartum abdominal pain, gastrointestinal (eg, nausea, vomiting).</td> </tr> <tr> <td>Carbetocin (not available in the United States)</td> <td><strong>IV or IM:</strong> 100 mcg once (administer IV over one minute).</td> <td>According to manufacturer labeling, use with caution in patients with asthma, epilepsy, migraine, or cardiovascular disease.</td> <td> <p>Similar to oxytocin.</p> Flushing, cardiovascular (eg, hypotension), headache, abdominal pain, gastrointestinal (eg, nausea).</td> </tr> <tr> <td>Tranexamic acid</td> <td><strong>IV:</strong> 1 g over 10 to 20 minutes once. Alternative 10 to 15 mg/kg over 10 to 20 minutes once.</td> <td>Some UpToDate contributors routinely use as adjunct to oxytocin in higher-risk settings (eg, for patients who refuse blood products or those with a significant risk for postpartum hemorrhage).</td> <td>Generally well tolerated; may increase risk of thrombotic events.</td> </tr> <tr> <td>Oxytocin-ergometrine (combination not available in the United States)</td> <td><strong>IM:</strong> Oxytocin 5 units and ergometrine 0.5 mg once.</td> <td>Refer to individual medications.</td> <td>Refer to individual medications.</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table lists medication options for active management of the third stage of labor for preventing postpartum hemorrhage. For selection of medication and combinations and timing of administration, refer to UpToDate clinical topic review and accompanying algorithm.</div><div class="graphic_footnotes"><p>IV: intravenous; NS: normal saline; IM: intramuscular.</p>
    
    * The optimal oxytocin infusion regimen has not been established; doses and durations vary among centers. To reduce risk of harm due to a medication error (eg, incorrect rate), UpToDate contributors recommend that labor units have available an institutionally approved protocol for oxytocin infusion that includes steps on how to prepare and administer the infusion by programmable infusion pump using standard concentration(s).</div><div class="graphic_reference">References:
    <ol>
<li>Lagrew D, McNulty J, Sakowski C, Cape V, McCormick E, Morton CH. Improving Health Care Response to Obstetric Hemorrhage, a California Maternal Quality Care Collaborative Toolkit, 2022.</li>
<li>Gallos ID, Papadopoulou A, Man R, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev 2018; 12:CD011689.</li>
<li>Lexicomp Online. Copyright Â© 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
<li>Sentilhes L, Vayssiere C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF) in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol 2016; 198:12.</li>
<li>Oladapo OT, Okusanya BO, Abalos E, et al. Intravenous versus intramuscular prophylactic oxytocin for the third stage of labour. Cochrane Database Syst Rev 2020; 11:CD009332.</li>
</ol></div><div id="graphicVersion">Graphic 129834 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
